Norditropin is an artificial growth hormone originally intended to be used for medical purposes only. But as often happens, athletes began to use the pharmacological agent over time. Growth hormone was developed for the treatment of children who are experiencing growth retardation, so its composition is as safe as possible for the body. The substance gained its popularity among athletes. It can be used to increase the overall endurance of the body, increase the intensity of training, and build muscle mass.
Packaging video review Norditropin Original 30 IU Novo Nordisk
ADVANTAGES OF THE GROWTH HORMONE NORDITROPIN NORDILET
The drug has a pronounced effect, due to which it is possible to stimulate the growth of cells and bone tissue. During the course, metabolic processes are significantly accelerated, which is especially important for athletes. The preparation contains synthetic somatropin, due to which the content of natural somatotropin is restored. Thanks to what, athletes:
increases muscle mass;
gets rid of adipose tissue;
gets great well-being and extra strength.
The use of growth hormone forces the body’s bone tissue to rebuild, which makes the skeleton more powerful and able to withstand the high loads that a bodybuilder faces. In the first time after the start of the course, weight loss begins, which is associated with the resorption process, after which there is a stable increase. It is possible to determine the appropriate dosage only individually, which depends on the state of the body and how it is able to tolerate the components of the drug.
EFFECTS OF APPLICATION NORDITROPIN NORDILET
The main effect of the drug Norditropin NordiLet is to stimulate the growth of the skeleton, muscle mass and a pronounced effect on metabolic processes.
In the treatment of growth hormone deficiency, body proportions are normalized, while muscle mass increases and fat mass decreases.
Most of the effects of somatropin are mediated through insulin-like growth factor I (IGF-I) — IGF-I, which is formed in many tissues of the body, but mainly in the liver. More than 90% of IGF-I form complexes with binding proteins (IGFBP), among which IGFBP-3 plays the most important role.
The lipolytic and protein-preserving effects of growth hormone play an important role in stress. Somatropin also increases the intensity of metabolic processes in bones, as evidenced by an increase in the concentration of bone tissue markers in blood plasma. In adult patients, in the first months of treatment, the bone mass decreases slightly due to a more pronounced resorption, but after prolonged treatment it increases.
any suspicion of the presence of an actively growing malignant tumor. Before starting treatment with growth hormone, it is necessary to make sure that the intracranial tumor is inactive and that anticancer therapy has been completed.
Severe patients with complications after surgery on the heart with an open chest, in the abdominal cavity, multiple trauma, acute respiratory failure, or similar conditions should not be prescribed the drug.
During pregnancy and breastfeeding. Hypersensitivity to any component of the drug.
In children with chronic kidney disease before kidney transplantation, treatment with Norditropin NordiLet should be discontinued.
Special security measures. Only transparent, colorless Norditropin NordiLet can be used. If, before the first injection, it was necessary to press the button more than 6 times to remove air from the syringe pen, such a drug should not be used.
Children receiving treatment with Norditropin NordiLet should undergo regular examinations by a specialist in the field of childhood growth pathology. Treatment with the drug should be prescribed by a physician specializing in the treatment of insufficient secretion of growth hormone. This also applies to the treatment of Turner syndrome and chronic kidney disease, as well as intrauterine growth retardation in children.
The drug is not prescribed as a growth stimulant for children with closed growth zones of the epiphyses of tubular bones.
Before starting treatment with growth hormone in children with chronic kidney disease, it is necessary to accurately establish whether they have growth disorders with optimal therapy for kidney pathology by observing for one year. During the period of use of the drug, it is necessary to continue conservative treatment of uremia with traditional drugs, and, if necessary, use dialysis.
In patients with chronic kidney disease, kidney function is usually reduced. As a precaution, kidney function should be constantly monitored during treatment with Norditropin NordiLet so as not to miss an excessive decrease or increase in the intensity of glomerular filtration (risk of hyperfiltration).
A small number of patients with growth hormone deficiency, some of whom were taking somatropin, had leukemia. But it is unlikely that it is associated with the intake of somatropin.
In patients with complete remission of benign or malignant tumors, the increased relapse rate is not associated with growth hormone treatment. Despite this, patients who have achieved complete remission of malignant growth should be monitored continuously in order not to miss a possible relapse after starting treatment with growth hormone.
Slipping of the epiphysis of the femoral head often occurs in patients with endocrine diseases, and Legg-Calve-Perthes disease often develops in people with short stature. With these diseases, lameness or pain in the hip or knee joints appears. Both doctors and relatives of the patient should be aware of this.
In the case of severe or recurrent headache, visual disturbances, nausea and / or vomiting, an ophthalmoscopy is recommended to check for swelling of the optic nerve. If it is confirmed, it can be assumed that a mild form of intracranial hypertension will develop. In this case, treatment with growth hormone should be discontinued.
Until now, the issue of managing patients in whom attacks of intracranial hypertension has stopped has not been finally resolved. When resuming growth hormone treatment, you should carefully monitor the possibility of her symptoms.
Replacement therapy with Norditropin NordiLet in adults with growth hormone deficiency should preferably be carried out under the supervision of an endocrinologist specializing in the treatment of pituitary pathology.
Growth hormone deficiency in adults is a lifelong condition that requires appropriate treatment. At the same time, the experience of treating patients over the age of 60 years and adult patients whose duration of treatment exceeds 5 years is still limited.
Children. The drug is used in children.
Ability to drive vehicles and work with potentially dangerous machinery. Does not affect.
acute overdose initially leads to hypoglycemia, subsequently to hyperglycemia. Hypoglycemia can only be detected by biochemical analysis (that is, there are no clinical symptoms). An overdose of the drug for a long time leads to the development of symptoms that occur with excessive production of growth hormone in the body.